News

Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...
AstraZeneca receives CDSCO approval for Durvalumab, a new treatment for muscle-invasive bladder cancer in India. This marks a ...
Bladder cancer symptoms often go unnoticed until it's too late. Learn the warning signs most people ignore and how early ...
Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.
Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.
The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...
In March, the company had received approval from the drug regulator to import and sell sodium zirconium cyclosilicate powder ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun ...
DelveInsight's, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline ...
A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the ...
Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...